GLP-1 / Unit conversion

Tirzepatide reconstitution calculator

Enter your Tirzepatide vial size, the volume of liquid added and the dose to calculate concentration and syringe units.

Your inputs determine the result. This calculator does not recommend dosages.

Live readout

Set your draw.

Enter your vial strength, diluent, and dose to see the draw.

Mode
Resulting concentration -- mg/mL
Doses per vial --
Syringe

Conversion follows standard mg, mL, and U-100 syringe references.

Performs unit conversions only. Not medical advice. Consult your healthcare provider.

Save preset

After saving, open Presets at the top of the calculator to recall this setup.

Saved presets

No saved presets

Save a conversion from the calculator to recall it later.

    Units chart

    Tirzepatide units chart (mg to U-100 units)

    Tirzepatide units chart: mg to U-100 units

    A tirzepatide amount and a syringe marking are connected by concentration. This chart uses 10 mg as an example vial size for arithmetic. It is not a labeled product: the label's product comes as ready-to-use solution in pens and vials and is not reconstituted.

    Vial concentration

    Water mL is treated as final solution mL in these columns.

    Tirzepatide: concentration in mg per mL
    Vial contents1 mL water2 mL water3 mL water
    10 mg10 mg/mL10 U-100 units per mg5 mg/mL20 U-100 units per mg3.3333 mg/mL30 U-100 units per mg

    Example vial size (input): 10 mg. No source is cited for this size; it is an arithmetic input, not a sourced fact.

    Amount to units

    Example amounts (arithmetic only, not doses).

    Tirzepatide: amount to U-100 syringe units
    Amount (mg)10 mg + 1 mL10 mg + 2 mL10 mg + 3 mL
    0.2 mg2 units4 units6 units
    0.5 mg5 units10 units15 units
    1 mg10 units20 units30 units
    2 mg20 units40 units60 units
    5 mg50 units100 units150 unitsover one syringe

    The label's amounts

    The label's product comes as ready-to-use solution in pens and vials and is not reconstituted. The rows below are the amounts its dosage section states.

    Tirzepatide: the label's amounts as its dosage section states them
    Amount (mg) and source contextFrequency as statedRoute as statedSource
    2.5 mgAdult label escalation step; increases are separated by at least 4 weeks. Once weeklySubcutaneous Tirzepatide prescribing information (2026)Regulatory labelRetrieved 2026-11-19
    5 mgAdult label escalation step; increases are separated by at least 4 weeks. Once weeklySubcutaneous Tirzepatide prescribing information (2026)Regulatory labelRetrieved 2026-11-19
    7.5 mgAdult label escalation step; increases are separated by at least 4 weeks. Once weeklySubcutaneous Tirzepatide prescribing information (2026)Regulatory labelRetrieved 2026-11-19
    10 mgAdult label escalation step; increases are separated by at least 4 weeks. Once weeklySubcutaneous Tirzepatide prescribing information (2026)Regulatory labelRetrieved 2026-11-19
    12.5 mgAdult label escalation step; increases are separated by at least 4 weeks. Once weeklySubcutaneous Tirzepatide prescribing information (2026)Regulatory labelRetrieved 2026-11-19
    15 mgAdult label escalation step; increases are separated by at least 4 weeks. Once weeklySubcutaneous Tirzepatide prescribing information (2026)Regulatory labelRetrieved 2026-11-19

    How to read this chart

    units = amount ÷ (vial mg ÷ water mL) × 100

    The reconstitution calculator walks through each step, and units to mg converts between mg, mcg, mL and units.

    Five days in the level model

    Tirzepatide has a stored elimination half-life of 120 hours, the label's approximately five days. The label's schedule is once weekly, so the interval between entries is longer than one modeled half-life. This distinction helps explain why the timeline covers the days between logged events rather than treating each event as an isolated point. The actual dates and times in a log position those events; the 120-hour value supplies the decay timescale used around them. Neither field changes the concentration of a vial.

    What the app stores about absorption

    The label states a mean absolute bioavailability of 80%, and the tirzepatide record uses that value. The label gives a time to peak of 8 to 72 hours. PinPoint's curve uses 20 hours, an app setting within that range. Reading the timing inputs as model settings keeps the hour-based level display distinct from the immediately calculated mL and syringe-unit values in these tables.

    The label's six amounts

    The label's amounts are 2.5, 5, 7.5, 10, 12.5, and 15 mg once weekly by subcutaneous injection, and its products are pens and vials of ready solution. The label block lists those amounts as the label gives them. This page does not turn them into syringe units, because the 10 mg example vial behind the arithmetic tables is not a labeled product.

    Following one row across the water columns

    The 10 mg tirzepatide vial amount is an example vial size (input). For the 1 mg arithmetic row, that is one tenth of the vial. One tenth of a 1 mL solution is 0.1 mL; one tenth of a 2 mL solution is 0.2 mL; one tenth of a 3 mL solution is 0.3 mL. The corresponding U-100 markings are 10, 20, and 30. This fraction-based reading explains why the columns differ even though the amount at the left of the row stays fixed.

    Units, mL and mg/mL

    Tirzepatide dosage in units and mL

    Searches for Tirzepatide dosage in units or in mL are conversion questions. Units and mL both measure volume, and what a volume holds depends on how the vial was mixed. The first table gives the concentration of a 10 mg Tirzepatide example vial (input) at 1, 2 and 3 mL of water; the second shows how many U-100 units each share of the vial takes, and what that share holds. Neither table sets a dose.

    Tirzepatide 10 mg vial: concentration, units per mg and what 10 units hold, by water volume
    Water added Concentration Units per 1 mg 10 units (0.1 mL) holds
    1 mL 10 mg/mL10,000 mcg/mL 10 units0.1 mL 1 mg1,000 mcg
    2 mL 5 mg/mL5,000 mcg/mL 20 units0.2 mL 0.5 mg500 mcg
    3 mL 3.33 mg/mL3,333.33 mcg/mL 30 units0.3 mL 0.3333 mg333.3 mcg
    Tirzepatide 10 mg vial: U-100 units per fraction of the vial, by water volume
    Fraction of the vial Holds Units in 1 mLUnits in 2 mLUnits in 3 mL
    1/20 one twentieth 0.5 mg500 mcg 5 units 0.05 mL 10 units 0.1 mL 15 units 0.15 mL
    1/10 one tenth 1 mg1,000 mcg 10 units 0.1 mL 20 units 0.2 mL 30 units 0.3 mL
    1/5 one fifth 2 mg2,000 mcg 20 units 0.2 mL 40 units 0.4 mL 60 units 0.6 mL
    1/4 one quarter 2.5 mg2,500 mcg 25 units 0.25 mL 50 units 0.5 mL 75 units 0.75 mL
    1/2 one half 5 mg5,000 mcg 50 units 0.5 mL 100 units 1 mL 150 units 1.5 mL over one 100-unit syringe

    Tirzepatide 10 mg reconstitution: worked example

    A 10 mg Tirzepatide vial mixed with 2 mL of bacteriostatic water holds 5 mg/mL, or 5,000 mcg/mL. On a U-100 syringe 10 units is 0.1 mL, and at this concentration it holds 0.5 mg (500 mcg), one twentieth of the vial. The whole 10 mg is 200 units at 2 mL, more than one 100-unit syringe holds. Mixed with 1 mL instead, the vial is 10 mg/mL and 10 units hold 1 mg; with 3 mL it is 3.33 mg/mL and 10 units hold 0.3333 mg.

    The fixed dose volumes in mL that the tirzepatide labels state for their pens and vials are on tirzepatide and semaglutide dose volumes in mL. This section converts a 10 mg example vial only.

    Arithmetic from the example vial size (input) shown, not doses. Water mL is treated as the final volume; a different vial entered in the calculator above gets the same formulas.

    Compound profile

    Tirzepatide at a glance

    Tirzepatide is a GIP and GLP-1 receptor agonist.[1] Under the cited label it is FDA-approved to improve blood sugar control in adults and children 10 years and older with type 2 diabetes, and to reduce the risk of major cardiovascular events in adults with type 2 diabetes at high risk. This page uses the label's half-life and absorption figures.[1]

    Regulatory status
    Tirzepatide is an FDA-approved prescription medicine; the cited label covers blood sugar control in adults and children 10 years and older with type 2 diabetes, and reducing the risk of major cardiovascular events in adults with type 2 diabetes at high risk.[1]
    Half-life
    Approximately 5 days (elimination half-life), enabling once-weekly dosing, per the label.[1]
    Route
    Subcutaneous, per the label.[1]
    Category
    GLP-1
    Label schedule
    Once weekly, per the label.[1]
    Vial size
    10 mg, example vial size (input)

    The tirzepatide facts connect two receptor targets to one generic record. The 120-hour time scale comes from prescribing information, whereas the 10 mg figure is an example vial size (input). Keeping those origins separate avoids reading an example container as a labeled device or research amount.[1]

    Evidence

    What the research says

    The label describes tirzepatide as a peptide acting at both GIP and GLP-1 receptors. Its pharmacokinetic program compared healthy participants with people who had type 2 diabetes and found similar disposition. Investigators followed plasma concentrations after subcutaneous administration to characterize exposure and elimination.[1]

    The label reports approximately 80% absolute bioavailability, a peak-concentration window of eight to 72 hours, and an elimination half-life of about five days. Exposure increases proportionally with dose. The wide peak window is part of the measured population description, rather than one fixed time for every participant.[1]

    The label's clinical studies measured HbA1c in adults and in children 10 years and older with type 2 diabetes, and cardiovascular events in a trial of 6,647 adults with type 2 diabetes and cardiovascular disease. Those clinical endpoints answer different questions from plasma drug concentrations. The labeled solution used in those programs is distinct from the example vial size used in the arithmetic.[1]

    Timing

    Half-life and timing

    Approximately 5 days (elimination half-life), enabling once-weekly dosing, per the label.[1]

    With 120 hours per halving, a one-starting-amount illustration reaches 50% at day five and 25% at day ten. The next three halvings place 12.5%, 6.25%, and 3.125% at days 15, 20, and 25. This sequence is deliberately simpler than a modeled history containing multiple entries. It also omits the eight- to 72-hour concentration-peak window described by the source. A graph's endpoint cannot answer when an individual has completely eliminated tirzepatide.[1]

    Read the Tirzepatide half-life on its label schedule page

    Calculator details

    About this calculation.

    What is the half-life of tirzepatide?

    The label gives an elimination half-life of approximately 5 days (120 hours). Five modeled half-lives span 600 hours. That arithmetic leaves 3.125% of the starting model amount, so it does not mean complete elimination or provide a personal waiting-period rule.[1]

    What information does a tirzepatide dosing calculator need?

    It needs independently known quantities, not merely the drug name. In a liquid example those include total compound, final volume, and the amount being converted. The calculator cannot obtain a clinically selected amount from the label's five-day half-life.[1]

    Does a tirzepatide half-life chart include the concentration peak?

    A simple half-life illustration begins with an abstract starting quantity and repeatedly halves it. The label's concentration-peak window concerns absorption after administration. That additional process is intentionally absent from this simple elimination illustration, so the illustration is not a complete exposure profile.[1]

    What concentration is Tirzepatide at 10 mg in 1 mL?

    10 mg divided by 1 mL is 10 mg per mL. That volume spans 100 U-100 syringe units.

    How does 2 mL change the concentration of this Tirzepatide vial?

    10 mg divided by 2 mL is 5 mg per mL, half the concentration in the 1 mL column.

    What does the 3 mL column mean for Tirzepatide?

    10 mg divided by 3 mL is approximately 3.3333 mg per mL. The full 3 mL volume corresponds to 300 U-100 units.

    How many units is 1 mg of Tirzepatide from this vial in 2 mL?

    1 mg divided by 5 mg per mL is 0.2 mL, or 20 U-100 units.

    References

    Sources

    Sources checked against the cited documents on 19 November 2026.

    1. Tirzepatide injection prescribing information (DailyMed, SPL effective 27 August 2026)Read 19 November 2026: 1, 2.1, 3, 12.1, 12.3, 14.Retrieved 2026-11-19 · label
    2. PinPoint App Store descriptionFeature wording from the approved application description, not pricing.Retrieved 2026-10-05 · app-description

    Keep your protocol together

    Track the result in the app.

    Set up vials, log doses and sites, and see your next reminder in PinPoint for iOS.

    Download on the App Store
    Syringe readout: 10 units is 0.10 mL on a U-100 insulin syringe
    THE ARITHMETIC / 0.10 mL = 10 UNITS

    Keep exploring

    More tools

    PinPoint app icon

    Your next chapter starts here

    Start Day 1 with
    your numbers in place.

    Your doses, your schedule, your picture. Bring it together in PinPoint.

    Built for iPhone.

    Subscription through the App Store, cancel anytime in your Apple ID settings.